FOSUN HEALTH Logo

Prostate Cancer Treatment

catalogue

Prostate Cancer Treatment

Prostate Cancer Treatment

Prostate cancer treatment has an unusual feature: for low-risk disease, the correct first move is often to watch rather than to act. Beyond that, the logic is straightforward — surgery or radiotherapy for disease confined to the gland, radiotherapy with hormone treatment for higher-risk localised disease, and systemic treatment for disease that has spread. Because cure rates for localised disease are similar across modalities, the side-effect profile often decides.

The plan by risk group

Prostate cancer treatment is chosen by risk category rather than by stage number, because the risk category already combines the three things that matter — PSA, grade group and extent:

Risk category Backbone What is added
Low risk Active surveillance with PSA, MRI and periodic biopsy Treatment only if the tumour shows signs of changing
Intermediate risk, favourable Nerve-sparing surgery or radiotherapy Short-course hormone treatment with radiotherapy in selected cases
Intermediate risk, unfavourable Surgery or radiotherapy Hormone treatment with radiotherapy usually added
High risk, localised Radiotherapy with long-course hormone treatment, or surgery in a combined plan Pelvic node treatment; adjuvant treatment decided by pathology
Metastatic, hormone-sensitive Testosterone suppression An androgen receptor pathway inhibitor or docetaxel added up front
Castration-resistant Continued testosterone suppression Further hormonal agents, chemotherapy, PSMA radioligand therapy, or PARP inhibitors by marker

Two features define modern practice. The first row is a treatment, not a postponement — surveillance with a defined schedule is the management of choice for low-risk disease, not a delay before the inevitable. And the bottom two rows are treated differently from each other: whether the disease still responds to testosterone suppression decides which drugs are added, which is why treatment is planned by that distinction rather than by stage alone.

Active surveillance

Active surveillance is the management of low-risk prostate cancer by close monitoring instead of immediate treatment. A typical programme combines PSA testing every few months, repeat MRI, and repeat biopsy at defined intervals, with treatment started only if the disease shows signs of changing — a rising grade group, a rising PSA trend, or new findings on imaging.

The rationale is specific rather than philosophical. Many grade group 1 tumours will never cause symptoms or shorten life, while surgery and radiotherapy both carry real effects on urinary and sexual function. Treating every diagnosis therefore trades a genuine side-effect burden for a benefit that many men would never have needed — and surveillance reserves treatment for the tumours that declare themselves.

It is, however, a commitment with two conditions. The monitoring schedule has to be followed — surveillance depends on the tests actually happening, and men who cannot attend regular follow-up are poor candidates. And it takes a certain temperament: living with a diagnosis that is being watched rather than treated suits some patients well and others badly, and that preference is a legitimate part of the choice, not an obstacle to it.

Radical prostatectomy

Radical prostatectomy removes the prostate and the seminal vesicles, and it is a curative operation for disease confined to the gland. Two aspects of how it is done matter to patients:

  • Nerve-sparing technique — the nerves that control erections run alongside the prostate in bundles that can be preserved when the tumour is positioned so that it is safe to do so. The decision is made during the operation, based on where the tumour sits, and it is the single biggest determinant of post-operative erectile function.
  • Minimally invasive approach — laparoscopic and robotic surgery have largely replaced open surgery, offering better magnification and instrument control, less blood loss and a shorter hospital stay, with a short-term continence advantage that narrows over time.

Recovery follows a predictable shape: a catheter for about a week, return to ordinary activity within a few weeks, and continence improving over weeks to months — with pelvic floor training starting early and making a measurable difference. A rising PSA level after surgery, if it occurs, is usually treated with radiotherapy to the prostate bed, guided by PSMA imaging where the level is low.

Radiotherapy

Radiotherapy treats the prostate from outside or from within, and for localised disease it achieves disease control comparable to surgery in the right patient. Three techniques are in routine use:

  • Intensity-modulated external-beam radiotherapy — dose is shaped to the gland while sparing the rectum and bladder; delivered over several weeks with daily image guidance.
  • Stereotactic body radiotherapy — a very precise, high-dose course given in a small number of sessions, suitable for lower-risk disease.
  • Brachytherapy — radioactive sources placed directly into the prostate, either as permanent seeds or as temporary high-dose-rate implants, alone for favourable disease or as a boost for higher-risk tumours.

The side-effect pattern differs from surgery in ways worth knowing before choosing. Urinary irritation and frequency are common during treatment and usually settle; bowel symptoms are usually mild with modern techniques; erectile function tends to decline gradually over years rather than abruptly, and continence is generally preserved better than after surgery. Because the two approaches offer comparable disease control, this side-effect profile — weighed against each patient's own priorities — is usually what decides the choice.

Hormone therapy

Prostate cancer depends on testosterone, and suppressing it is the single most effective systemic treatment for the disease. Androgen deprivation therapy is given in three situations, with very different intentions:

  • With radiotherapy for higher-risk localised disease — typically for one to three years, where it improves the effectiveness of the radiotherapy rather than treating spread.
  • For metastatic hormone-sensitive disease — as the backbone of treatment, now usually intensified with an androgen receptor pathway inhibitor or chemotherapy from the outset rather than reserved for later.
  • For castration-resistant disease — continued in the background while other agents are added, because the cancer has found ways to grow despite it.

The side effects are a genuine part of the treatment and are worth discussing before starting: hot flushes, loss of libido and erectile function, fatigue, loss of muscle mass with weight gain, mood changes, and — over the long term — reduced bone density and a higher risk of diabetes and cardiovascular events. Most are manageable with exercise, resistance training, bone protection and attention to cardiovascular risk factors, which is why hormone therapy is now planned as a package rather than as a single injection.

Systemic treatment for advanced disease

Advanced prostate cancer has more effective systemic options than it did a decade ago, and the choice is driven by whether the disease still responds to testosterone suppression and by what the markers show:

  • Androgen receptor pathway inhibitors — abiraterone, enzalutamide, apalutamide and darolutamide, used both in hormone-sensitive and castration-resistant disease; they act on the receptor the tumour depends on.
  • Docetaxel chemotherapy — improves survival in hormone-sensitive and castration-resistant disease, and is often combined with hormonal treatment up front in high-volume metastatic disease.
  • PSMA radioligand therapy — a radioactive agent that binds PSMA on cancer cells, delivering radiation directly to deposits; used in advanced disease after other options, and requires PSMA imaging to confirm uptake.
  • PARP inhibitors — effective in tumours with BRCA2 or other DNA repair gene faults, which is why germline and tumour testing should be requested in advanced disease.
  • Immune checkpoint inhibitors — for the small proportion of tumours with mismatch repair deficiency, where they can produce durable responses.

The practical consequence: for metastatic disease, the useful questions are whether PSMA imaging has been done, whether germline genetic testing has been done, and whether the treatment plan was intensified from the start rather than sequenced one drug at a time. Each of those three changes what is available.

Bone health and bone metastases

Prostate cancer has a predilection for bone, and two separate issues follow from that. The first is the skeleton under long-term hormone therapy: testosterone suppression accelerates bone loss, and men on prolonged treatment should have bone density assessed and take vitamin D and calcium, with a bone-modifying agent where density is low. Resistance exercise works on the same problem from the other direction.

The second is established bone metastases. These are managed with a bone-modifying agent — denosumab or a bisphosphonate — to reduce the risk of fracture and skeletal complications, together with adequate pain control and, where a deposit threatens stability or the spinal cord, local radiotherapy or surgery. New persistent back pain in a man with prostate cancer is therefore never assumed to be muscular: it is assessed promptly, because spinal cord compression is a time-critical event and the window for protecting walking function is measured in hours to days.

How the decision is made

Prostate cancer decisions sit between urology, radiation oncology, medical oncology and pathology, and the debate is genuinely balanced for localised disease — which is exactly why it belongs to a team rather than to one specialist. Our MDT reviews each file against the same grid: the PSA history, the grade group and the proportion of pattern 4, where the tumour sits within the gland, the MRI and any PSMA findings, and the patient's age, general health, urinary and sexual function before treatment, and his own priorities.

The output is a written plan that names both routes where both are reasonable, states what each would mean for continence, erectile function and bowel habit, and pre-decides what follows under each plausible pathology result. For international patients the MDT works on records alone, and the written assessment returns within 48 hours of the file being complete — including, where the file is incomplete, exactly which two or three items would change the recommendation.

Frequently Asked Questions

Is active surveillance the same as doing nothing?

No — it is a defined management strategy with a schedule. PSA testing every few months, repeat MRI and repeat biopsy at set intervals, with treatment started promptly if the grade group rises or the PSA trend changes. The point is to avoid treating a tumour that will never cause harm while catching the ones that do show signs of changing. Men in surveillance are followed more closely than most patients on treatment, and the commitment to attend follow-up is what makes it safe.

How do I choose between surgery and radiotherapy?

For disease confined to the gland, the two control it comparably in the right patient, so the decision usually turns on side effects and practicalities. Surgery is a single intervention with a recovery period and a catheter for about a week, and its main long-term trade-offs are continence and erectile function. Radiotherapy is a course of treatment over weeks with a gradual effect on erectile function and usually better preservation of continence, with mild bowel symptoms in a minority. Because the disease control is comparable, your own priorities are a legitimate deciding factor.

Will hormone therapy be needed, and for how long?

It depends entirely on the category. For low-risk disease treated with surgery, usually not at all. For higher-risk localised disease treated with radiotherapy, commonly one to three years — there it makes the radiotherapy work better rather than treating spread. For metastatic disease it is the backbone of treatment continued indefinitely, usually intensified with another agent from the start. The side effects are real, and the plan should state the intended duration before starting, not leave it open.

What if the PSA rises again after treatment?

It depends on which treatment was given and where the disease is. After surgery, a rising PSA is usually treated with radiotherapy to the prostate bed, with PSMA imaging to locate the source when the level is low. After radiotherapy, salvage options include hormone treatment and, in selected cases, local procedures. Because PSMA PET-CT can now localise recurrence at very low PSA levels, the useful step is to image early rather than to wait for a level that older scans could see — the treatment that follows is far more targeted as a result.

Patient Stories

Stories from our prostate cancer programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

See both routes before deciding

The choice between surgery and radiotherapy is a decision about side effects as much as about cancer. Upload the PSA history, biopsy report and imaging, and our urological oncology MDT will set out both routes and what each implies for you — in writing, within 48 hours.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*